Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The aim of this study was to evaluate the therapeutic effects of chlorogenic acid (CGA) in rats with advanced alcoholic steatohepatitis. The rats were fed on a high-fat diet and gavaged with ethanol (4 g/kg) for 8 weeks. The livers of ethanol-treated rats showed steatosis; necrosis and mononuclear infiltration; and significant upregulation of the mRNA expression of the prooxidant (Cyp2e1, iNos), lipogenic (Srebp1, Acc), proinflammatory (Tlr4, Nf-κb, TnfA, Il-1B, and Il-6), and profibrogenic (TgfB, Col1, VegfA) genes. Simultaneously, a downregulation of level of and was observed, which was accompanied by increased serum transaminase, TnfA, and serum and liver triglycerides levels. CGA administration (40 and 80 mg/kg, 8 weeks) to ethanol-fed group reduced the liver expression levels of and , whereas it markedly enhanced the expression of , , and . CGA at both doses downregulated the expressions of lipogenic, proinflammatory, and profibrogenic genes, while the expression of was lowered only after the higher dose of CGA. The higher dose of CGA efficiently prevented the progression of alcohol-induced steatosis and reduced inflammation through regulation of the expression of genes encoding the proteins involved in the Tlr4/Nf-κB signaling pathway and fibrosis. The study revealed hepatoprotective and anti-inflammatory effects of CGA through the regulation of expression of genes encoding Cyp2e1/Nrf2 involved in oxidative stress modulation. These results demonstrate CGA as a therapeutic candidate for the prevention and treatment of alcoholic steatohepatitis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617701PMC
http://dx.doi.org/10.3390/nu13114155DOI Listing

Publication Analysis

Top Keywords

alcoholic steatohepatitis
12
chlorogenic acid
8
advanced alcoholic
8
steatohepatitis rats
8
higher dose
8
dose cga
8
regulation expression
8
expression genes
8
genes encoding
8
cga
7

Similar Publications

Background: This study aimed to investigate the gender-specific associations of skeletal muscle mass and fat mass with non-alcoholic fatty liver disease (NAFLD) and NAFLD-related liver fibrosis in two population-based studies.

Methods: Analyses were based on data from the MEGA (n = 238) and the MEIA study (n = 594) conducted between 2018 and 2023 in Augsburg, Germany. Bioelectrical impedance analysis was used to evaluate relative skeletal muscle mass (rSM) and SM index (SMI) as well as relative fat mass (rFM) and FM index (FMI); furthermore, the fat-to-muscle ratio was built.

View Article and Find Full Text PDF

Background And Aims: Diabetes mellitus (DM) commonly coexists with non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD), and when combined with these two conditions, the risk of all-cause mortality and developing cardiovascular diseases (CVD) increases. The present community-based cohort study aimed to elucidate the combined effect of NAFLD and CKD on CVD and mortality risks in new-onset DM patients.

Methods And Results: After the exclusion of participants failing to meet the inclusion criteria, 11,328 eligible participants (mean age: 58.

View Article and Find Full Text PDF

Background And Aims: Obesity-related non-alcoholic fatty liver disease (NAFLD) and serum high-sensitivity C-reactive protein (hs-CRP) are known to be associated to some extent. Nevertheless, this relationship remains unclear in non-obese individuals.

Methods And Results: A prospective cohort study was conducted using data from the health check ups of employees at Zhenhai Refining and Chemical Hospital in Ningbo City.

View Article and Find Full Text PDF

This study explores how human antigen R (HuR) stabilizes fibroblast growth factor 19 (FGF19) mRNA, inhibiting Kupffer cell (KC) activation to reduce inflammation and fibrosis in non-alcoholic fatty liver disease (NAFLD). An animal model of NAFLD was established in mice by administering a high-fat diet (HFD). In vitro study utilized a lipopolysaccharide-induced immortalized mouse KC model.

View Article and Find Full Text PDF

Increasing evidence indicates a potential link between macrophage colony-stimulating factor 1 (CSF1) and macrophage migration inhibitory factor (MIF) with nonalcoholic fatty liver disease (NAFLD). However, the causal relationships remain unclear. This study aims to clarify the causal associations between CSF1, MIF, and NAFLD using Mendelian randomization (MR) analysis.

View Article and Find Full Text PDF